Tan et al. studied the profiles of 28 chronically infected HBeAg+ patients early in their treatment course. Rapid upregulation of the IFN signalling pathway by PEG-IFNα occurred concurrently with increased detection of IL-15, IL-6, CXCL-10 and upregulated frequency of proliferating NK and activated total CD8+ T cells. Inhibiting HBV replication with tenofovir disoproxil fumarate partly compensated for the diminished immune response after the first PEG-IFNα dose.
ORIGINAL RESEARCH PAPER
Tan, A. T. et al. Reduction of HBV replication prolongs the early immunological response to IFNα therapy. J. Hepatol. doi:10.1016/j.hep2013.08.020
Rights and permissions
About this article
Cite this article
Early immunological response to IFNα therapy benefits from suppressed HBV replication. Nat Rev Gastroenterol Hepatol 10, 564 (2013). https://doi.org/10.1038/nrgastro.2013.191
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2013.191
